Budd-Chiari syndrome laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(14 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Budd-Chiari syndrome}}
{{Budd-Chiari syndrome}}
{{CMG}}
{{CMG}}; {{AE}}{{Mazia}}
 
==Overview==
Budd-Chiari syndrome should be suspected in patients with predisposing conditions such as [[malignancy]] or [[hypercoagulable states]]. When Budd-Chiari syndrome is suspected, [[liver function tests]] and levels of [[creatinine]], [[urea]], [[Electrolyte|electrolytes]], [[LDH]] should be evlauated. [[Liver biopsy]] for the presence of [[antiphospholipid antibodies]] is usually tested for [[patients]] with primary BCS. [[Bone marrow biopsy]] can be used to diagnose associated [[Myeloproliferative disease|myeloproliferative disorders]], which are common in BCS. Laboratory findings consistent with the [[diagnosis]] of [[acute]] and [[fulminant]] BCS include, elevated [[Aspartate aminotransferase|serum aspartate aminotransferase]] and [[alanine aminotransferase]] levels (may be more than five times the upper limit of the normal range) and elevated [[Alkaline phosphatase|serum alkaline phosphatase]] and [[bilirubin]] levels, decreased [[Albumin|serum albumin level]]. [[Ascitic]] fluid examination shows: [[Total protein]] more than 2.5 g per deciliter and [[white blood cells]] are usually less than 500/μL. Additional [[hematological]] tests are recommended to evaluate for [[hypercoagulability]].


==Laboratory Findings==
==Laboratory Findings==
When Budd-Chiari syndrome is suspected, measurements are made of
*Suspect Budd-Chiari syndrome in patients with predisposing conditions such as [[malignancy]] or [[hypercoagulable states]].
 
*When Budd-Chiari syndrome is suspected, measurements are made of:<ref name="pmid28922103">{{cite journal |vauthors=Grus T, Lambert L, Grusová G, Banerjee R, Burgetová A |title=Budd-Chiari Syndrome |journal=Prague Med Rep |volume=118 |issue=2-3 |pages=69–80 |year=2017 |pmid=28922103 |doi=10.14712/23362936.2017.6 |url=}}</ref><ref name="pmid24923240">{{cite journal |vauthors=Copelan A, Remer EM, Sands M, Nghiem H, Kapoor B |title=Diagnosis and management of Budd Chiari syndrome: an update |journal=Cardiovasc Intervent Radiol |volume=38 |issue=1 |pages=1–12 |year=2015 |pmid=24923240 |doi=10.1007/s00270-014-0919-9 |url=}}</ref>
* [[Liver enzyme]] levels
**[[Liver enzyme]] levels
* [[Creatinine]]
**[[Electrolyte]]s
* [[Urea]]
**[[Alkaline phosphatase|Serum alkaline phosphatase levels]]
* [[Electrolyte]]s
**[[Creatinine]]
* [[lactate dehydrogenase|LDH]]).
**[[Urea]]
* [[Liver biopsy]] is nonspecific but sometimes necessary to differentiate between Budd-Chiari syndrome and other causes of hepatomegaly and ascites, such as [[galactosemia]] or [[Reye's syndrome]]
**[[Ascites Paracentesis|Ascitic fluid analysis]]
* Severe hepatic [[necrosis]] and [[lactic acidosis]] may be present as well.  Caudate lobe hypertrophy is often present. The majority of patients have a slower-onset form of Budd-Chiari syndrome. This can be painless.   Patients may progress to [[cirrhosis]] and show the signs of liver failure.
**[[lactate dehydrogenase|LDH]]
**[[Liver biopsy]] is nonspecific but sometimes necessary to differentiate between Budd-Chiari syndrome and other causes of [[hepatomegaly]] and [[ascites]], such as [[galactosemia]] or [[Reye's syndrome]].
**[[Factor V Leiden]] and [[Factor II|Factor II (prothrombin) mutations]], for the presence of [[antiphospholipid antibodies]], is usually tested for patients with primary BCS.
**[[Bone marrow biopsy]] can be used to diagnose associated [[Myeloproliferative disease|myeloproliferative disorders]] are common in BCS.
*Laboratory findings consistent with the [[diagnosis]] of [[acute]] and [[fulminant]] BCS include:
**Elevated [[Aspartate aminotransferase|serum aspartate aminotransferase]] and [[alanine aminotransferase]] levels may be more than five times the upper limit of the normal range.
**Elevated serum [[alkaline phosphatase]] and [[Bilirubin|bilirubin levels]], decreased [[Albumin|serum albumin level]].
*[[Ascitic tap|Ascitic fluid examination]] shows:
**[[Total protein]] more than 2.5 g per deciliter
**[[White blood cells]] are usually less than 500/μL.
*Additional Hematological tests are recommended to evaluate for [[hypercoagulability]].


==References==
==References==
{{Reflist|2}}


{{Reflist|2}}
[[Category:Hepatology]]
[[Category:hepatology]]
[[Category:Disease]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Needs overview]]
[[Category:Needs overview]]

Latest revision as of 19:51, 30 November 2017

Budd-Chiari syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Budd-Chiari syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Budd-Chiari syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Budd-Chiari syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Budd-Chiari syndrome laboratory findings

CDC on Budd-Chiari syndrome laboratory findings

Budd-Chiari syndrome laboratory findings in the news

Blogs on Budd-Chiari syndrome laboratory findings

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Budd-Chiari syndrome laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

Budd-Chiari syndrome should be suspected in patients with predisposing conditions such as malignancy or hypercoagulable states. When Budd-Chiari syndrome is suspected, liver function tests and levels of creatinine, urea, electrolytes, LDH should be evlauated. Liver biopsy for the presence of antiphospholipid antibodies is usually tested for patients with primary BCS. Bone marrow biopsy can be used to diagnose associated myeloproliferative disorders, which are common in BCS. Laboratory findings consistent with the diagnosis of acute and fulminant BCS include, elevated serum aspartate aminotransferase and alanine aminotransferase levels (may be more than five times the upper limit of the normal range) and elevated serum alkaline phosphatase and bilirubin levels, decreased serum albumin level. Ascitic fluid examination shows: Total protein more than 2.5 g per deciliter and white blood cells are usually less than 500/μL. Additional hematological tests are recommended to evaluate for hypercoagulability.

Laboratory Findings

References

  1. Grus T, Lambert L, Grusová G, Banerjee R, Burgetová A (2017). "Budd-Chiari Syndrome". Prague Med Rep. 118 (2–3): 69–80. doi:10.14712/23362936.2017.6. PMID 28922103.
  2. Copelan A, Remer EM, Sands M, Nghiem H, Kapoor B (2015). "Diagnosis and management of Budd Chiari syndrome: an update". Cardiovasc Intervent Radiol. 38 (1): 1–12. doi:10.1007/s00270-014-0919-9. PMID 24923240.